Core Viewpoint - JP Morgan Chase shares have seen a significant rise following an upgrade from HSBC, with a price target set at $319, despite a slow start to 2026 [1] Group 1: Stock Performance - JP Morgan shares are mostly unchanged year-to-date but have rallied over 50% from April lows and are only 4% off all-time highs [1] - The bank is outperforming the S&P and the XLF financial ETF, although it is trailing behind other major banks like Citigroup, Goldman Sachs, and Bank of America [2][3] Group 2: Market Environment - The recent upgrades from HSBC and Bar, with Bar upgrading to neutral from sell and maintaining a $280 price target, indicate a positive environment for big banks [4] - The overall trajectory for major banks appears to be upward, with a general uptrend observed in recent weeks [3] Group 3: Technical Analysis - JP Morgan's stock has been rangebound this year, with significant price movements contained within established boundaries [5][6] - Current resistance levels are identified between $318 and $323, with a potential for traction if the price crosses above this range [7][8] - The stock has shown signs of trend improvement, breaking through a shorter-term downtrend and closing above key moving averages [9][10] Group 4: Options Activity - There has been an increase in options activity, with a notable 1.6% rise in volume compared to the 5-day moving average, indicating heightened interest [12] - A bearish trade involving 750 May 15th, 300 strike puts was noted, suggesting some market participants are hedging against potential declines [13]

Core Viewpoint - The Dow Jones Industrial Average has surpassed the 50,000 points milestone for the first time, indicating strong market performance and investor confidence [1] Company Performance - Nvidia's stock increased by over 7%, reflecting positive market sentiment and strong demand for its products [1] - Caterpillar's shares rose by more than 6%, suggesting robust performance in the industrial sector [1] - Goldman Sachs and JPMorgan both saw their stock prices rise by over 4%, indicating strong financial sector performance [1] - Disney and IBM experienced stock increases of over 3%, highlighting positive developments in the entertainment and technology sectors [1] - UnitedHealth, Walmart, and Cisco all had stock price increases of over 2%, demonstrating resilience in the healthcare, retail, and technology industries [1]

Core Viewpoint - Morgan Stanley has reduced its stake in WuXi AppTec (02359) by 798,119 shares at a price of HKD 109.1481 per share, totaling approximately HKD 87.1132 million, resulting in a new holding of about 35.2451 million shares, representing 6.90% of the company [1] Summary by Category - **Share Reduction** - Morgan Stanley sold 798,119 shares of WuXi AppTec [1] - The sale price was HKD 109.1481 per share [1] - The total amount from the sale was approximately HKD 87.1132 million [1] - **Current Holdings** - After the reduction, Morgan Stanley's remaining shares in WuXi AppTec are approximately 35.2451 million [1] - The new ownership percentage is 6.90% [1]

Group 1 - Morgan Stanley reduced its stake in Kelaiying (002821) (06821) by 19,800 shares at a price of 78.6378 HKD per share, totaling approximately 1.557 million HKD [1] - After the reduction, Morgan Stanley's latest holding is approximately 1.668 million shares, representing a holding percentage of 5.99% [1]

Group 1 - Morgan Stanley increased its stake in Jinli Permanent Magnet (06680) by 1,382,047 shares at a price of HKD 21.151 per share, totaling approximately HKD 29.23 million [1] - After the increase, the total number of shares held by Morgan Stanley is approximately 17,431,000, representing a holding percentage of 7.42% [1]

Core Viewpoint - Morgan Stanley has reduced its stake in WuXi AppTec (02359) by selling 798,119 shares at a price of HKD 109.1481 per share, totaling approximately HKD 87.1132 million, resulting in a new holding of about 35.2451 million shares, representing 6.90% of the company [1] Group 1 - Morgan Stanley sold 798,119 shares of WuXi AppTec on February 3 [1] - The selling price per share was HKD 109.1481, leading to a total transaction value of approximately HKD 87.1132 million [1] - After the sale, Morgan Stanley's remaining shares in WuXi AppTec are approximately 35.2451 million, which constitutes a 6.90% ownership stake [1]

Group 1 - Morgan Stanley increased its stake in Innovent Biologics (01801) by 1,233,667 shares at a price of HKD 78.6975 per share, totaling approximately HKD 97.0865 million [1] - Following the increase, Morgan Stanley's total shareholding in Innovent Biologics reached approximately 87,914,900 shares, representing a stake of 5.06% [1]

| 版Page Bar | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股每股的平均價 | | | | 四麻生堂品游费用技 | 佔已發行的 有關事件的日 | | --- | --- | --- | --- | --- | --- | --- | | | 份题目 | 原因 | | | | (請參閱上述*註解)有按票權股(日/月/年 | | | | | | | | 分自分比 | | CS20260206E00374 | JPMorgan Chase & Co. | 1101(L) | 1.527.366(L | HKD 11.1598 | 63.066.166(L) | 14.27(L)03/02/2026 | | | | 14015(S) | 1,491,366(S) | | 13,856,068(S) | 3.13(S) | | | | | | | 6,273,701(P) | 1.42(P) | 格隆汇2月6日丨根据联交所最新权益披露资料显示，2026年2月3日，福莱特玻璃(06865.HK)获JPMorgan Chase & Co.以每股均价11.1598港元增持好仓152.74 万 ...

| 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 費出或涉及的股每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日 | | | --- | --- | --- | --- | --- | --- | --- | | | | 景区 | 份致目 | | (請參閱上述 * 註解) 有投票權股 (日 / 月 / 年 (觉自分成 | | | | | | | | ( % ) | | | CS20260206E00371 | JPMorgan Chase & Co. 1101(L) 1,382,047(L) | | | HKD 21.1510 | 17.430.951(L) | 7.42(L)03/02/2026 | | | | | | | 13.789.549(S) | 5.87 (S) | | | | | | | 3 689 270/P) | 157(P) | 格隆汇2月6日丨根据联交所最新权益披露资料显示，2026年2月3日，金力永磁(06680.HK)获JPMorgan Chase & Co.以每股均价21.151港元增持好仓138.20万 股，涉资约2923.2万港元 ...

Group 1 - JPMorgan Chase & Co. increased its stake in China Pacific Insurance (02328.HK) by acquiring 6.907 million shares at an average price of HKD 15.8139 per share, totaling approximately HKD 109 million [1] - Following the acquisition, JPMorgan's total holdings in China Pacific Insurance rose to 623,687,007 shares, increasing its ownership percentage from 8.93% to 9.03% [1]